Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
65/100
Pipeline Velocity
34/100
Trial Completion Rate
92/100
Pipeline Concentration
50/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use Disorder
Olfactory Function and Model-based Behavior in People Living With HIV and SUD
Environment and Alcohol: A Pilot Study
Defining Neurobiological Links Between Substance Use and Mental Illness
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Multimodal Neuroimaging Genetic Biomarkers of Nicotine Addiction Severity
Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Parasal — PARASAL
Application NDA006811 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)